Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Lymphoma, AIDS-Related 1 Lymphoma 1 HIV Infections 1 Acquired Immunodeficiency Syndrome 1

Interventions

Docetaxel 56 Prednisone 36 enzalutamide 25 Leuprolide 24 Magnetic Resonance Spectroscopy 19 Abiraterone Acetate 19 bicalutamide 17 Radiotherapy 15 Goserelin 15 abiraterone 12 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11 olaparib 9 Androgen Antagonists 9 gallium 68 PSMA-11 8 cabazitaxel 8 Radiotherapy, Intensity-Modulated 8 Metformin 8 Ketoconazole 8 Gonadotropin-Releasing Hormone 8 Cyclophosphamide 8 apalutamide 7 Doxorubicin 7 luprolide acetate gel depot 6 cabozantinib 6 Radiosurgery 6 Estramustine 6 Dexamethasone 6 Calcitriol 6 Biopsy 6 pembrolizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Prostatic Neoplasms × Genes × Clear all

NCT03152448 2022-06-13

P-PROVE

Myriad Genetic Laboratories, Inc.

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡